Trafalgar International (GCAN) EBITDA Margin (2017 - 2021)
Trafalgar International (GCAN) posted EBITDA Margin of 494.65% for Q2 2021, down 190.16% on a QoQ basis from 170.47% in Q2 2020, and down 32417.0% year-over-year from N/an in Q2 2020.
Analysis
Trafalgar International (GCAN) EBITDA Margin (2017 - 2021) Analysis & Trends
Trafalgar International has reported EBITDA Margin for 5 years, with the latest figure at 494.65% in Q2 2021.
- On a quarterly basis, EBITDA Margin fell 32417.0% year-over-year to 494.65% in Q2 2021; TTM through Dec 2021 was 2716.91%, a 215651.0% decrease from a year earlier, with the FY2021 full-year figure at 2716.91%, down 210402.0% from the prior year.
- EBITDA Margin was 494.65% for Q2 2021 at Trafalgar International, down from 170.47% in the prior quarter.
- The five-year high for EBITDA Margin was 99.52% in Q1 2018, with the low at 43656.16% in Q2 2017.
- Average EBITDA Margin over 5 years is 10037.53%, with a median of 1744.25% recorded in 2019.
- The sharpest annual moves came in 2018 and 2021: EBITDA Margin surged 4375550 bps in 2018, then tumbled 32417 bps in 2021.
- Over 5 years, EBITDA Margin stood at 28856.62% in 2017, then surged by 100 bps to 99.34% in 2018, then plunged by 4456 bps to 4327.33% in 2019, then surged by 96 bps to 170.47% in 2020, then sank by 190 bps to 494.65% in 2021.
- The last three EBITDA Margin figures came in at 494.65% (Q2 2021), 170.47% (Q2 2020), and 4327.33% (Q4 2019), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.00 Bn | 621.25 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 446.05 Bn | 439.48 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 357.71 Bn | 350.56 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 268.09 Bn | 260.40 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 156.78 Bn | 145.08 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 52.12 Bn | 44.74 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 43.05 Bn | 43.05 Bn | - | - |
| 8 | Incyte | 24.84 Bn | 20.31 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 21.39 Bn | 18.73 Bn | 683.80 Mn | 42.23% |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -494.65% |
| Jun 30, 2020 | -170.47% |
| Dec 31, 2019 | -4,327.33% |
| Sep 30, 2019 | -2,993.85% |
| Jun 30, 2018 | 99.34% |
| Mar 31, 2018 | 99.52% |
| Sep 30, 2017 | -28,856.62% |
| Jun 30, 2017 | -43,656.16% |